Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
50
ARGNF Quote, Financials, Valuation and Earnings
Last price:
$814.94
Seasonality move
:
1.38%
Day range:
$814.94 - $814.94
52-week range:
$532.40 - $872.27
Dividend yield:
0%
P/E ratio:
41.64x
P/S ratio:
12.82x
P/B ratio:
5.50x
Volume:
--
Avg. volume:
191
1-year change:
16.85%
Market cap:
$50.4B
Revenue:
$4.2B
EPS (TTM):
$19.57
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, argenx SE has -- downside to fair value with a price target of -- per share.
ARGNF vs. S&P 500
-
Over the past 5 trading days, argenx SE has overperformed the S&P 500 by 2.06% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
argenx SE does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
argenx SE has grown year-over-year revenues for 12 quarters straight. In the most recent quarter argenx SE reported revenues of $948M.
Earnings Growth
-
argenx SE has grown year-over-year earnings for 0 quarters straight. In the most recent quarter argenx SE reported earnings per share of $3.74.
Enterprise value:
50.4B
EV / Invested capital:
--
Price / LTM sales:
12.82x
EV / EBIT:
51.99x
EV / Revenue:
12.14x
PEG ratio (5yr expected):
--
EV / Free cash flow:
68.47x
Price / Operating cash flow:
119.76x
Enterprise value / EBITDA:
50.53x
Gross Profit (TTM):
$3.7B
Return On Assets:
21.14%
Net Income Margin (TTM):
31.12%
Return On Equity:
28.06%
Return On Invested Capital:
24.23%
Operating Margin:
21.5%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | $801.8M | $1.6B | $3.1B | $474.9M | $948M | |
| Gross Profit | $630.6M | $1.3B | $2.7B | $422.5M | $837.2M | |
| Operating Income | -$564M | -$399.3M | $392.2M | -$43.9M | $203.8M | |
| EBITDA | -$458.2M | -$287.4M | $414.4M | -$14.4M | $288M | |
| Diluted EPS | -$7.15 | -$3.50 | $19.65 | $0.49 | $3.74 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.5B | $2.8B | $4.1B | $4.9B | -- | |
| Total Assets | $2.9B | $3.1B | $4.5B | $6.2B | -- | |
| Current Liabilities | $301.2M | $302.3M | $423M | $669.9M | -- | |
| Total Liabilities | $316.1M | $320.6M | $445M | $704.2M | -- | |
| Total Equity | $2.5B | $2.8B | $4.1B | $5.5B | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$650.9M | -$145.3M | $539.4M | -$124.7M | $361.8M | |
| Cash From Investing | $242.8M | -$847M | -$277.2M | -$513.8M | $62.3M | |
| Cash From Financing | $156.3M | $1.3B | $313.2M | $40.1M | $73.5M | |
| Free Cash Flow | -$755.1M | -$211M | $444.3M | -$147M | $312.8M | |
ARGNF
Sector
Market Cap
$50.4B
$25.7M
Price % of 52-Week High
93.43%
50%
Dividend Yield
0%
0%
Shareholder Yield
-0.52%
-1.64%
1-Year Price Total Return
16.85%
-18.75%
Beta (5-Year)
-0.425
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$814.94
200-day SMA
Buy
Level
$738.82
Bollinger Bands (100)
Sell
Level
816.02 - 866.04
Chaikin Money Flow
Sell
Level
-32.5K
20-day SMA
Sell
Level
$816.33
Relative Strength Index (RSI14)
Sell
Level
38.39
ADX Line
Sell
Level
57.27
Williams %R
Neutral
Level
-54.2921
50-day SMA
Sell
Level
$828.12
MACD (12, 26)
Sell
Level
-4.27
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
1.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (25.2109)
Buy
CA Score
(Annual)
Level (1.9999)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-5.5736)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
Stock Forecast FAQ
In the current month, ARGNF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ARGNF average analyst price target in the past 3 months is --.
-
Where Will argenx SE Stock Be In 1 Year?
According to analysts, the consensus estimate is that argenx SE share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About argenx SE?
Analysts are divided on their view about argenx SE share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that argenx SE is a Sell and believe this share price will rise from its current level to --.
-
What Is argenx SE's Price Target?
The price target for argenx SE over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ARGNF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for argenx SE is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ARGNF?
You can purchase shares of argenx SE via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase argenx SE shares.
-
What Is The argenx SE Share Price Today?
argenx SE was last trading at $814.94 per share. This represents the most recent stock quote for argenx SE. Yesterday, argenx SE closed at $814.94 per share.
-
How To Buy argenx SE Stock Online?
In order to purchase argenx SE stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ARGNF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ARGNF
Sector
P/E ratio
41.64x
22.00x
PEG ratio
--
-0.01x
P/B ratio
5.50x
1.78x
Price / LTM sales
12.82x
1.49x
Growth Metrics
ARGNF
Sector
Revenue growth
99.61%
3.28%
Earnings growth
663.27%
12%
Revenue (5-year growth)
151.52%
6.3%
Earnings forecast
--
-$0.20
Profitability
ARGNF
Sector
Profitability FY 2025
$3.7B
$2.4M
Return on invested capital
24.23%
-33.43%
Return on assets
21.14%
-30.04%
Return on equity
28.06%
-40.01%
Earnings Date
Last Earnings Date
Feb
26
Next Earnings Date
May
7
Estimated Next Earnings Date
May
28
Balance Sheet
ARGNF
Sector
Total cash
$3.9B
$24.1M
Short term investments
$1.9B
$23.2M
Total assets
$8.7B
$69.8M
Long term debt
--
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
68
XENE alert for Mar 10
Xenon Pharmaceuticals, Inc. [XENE] is down 3.44% over the past day.
Sell
32
BNTX alert for Mar 10
BioNTech SE [BNTX] is down 17.94% over the past day.
Buy
52
MLAB alert for Mar 10
Mesa Laboratories, Inc. [MLAB] is down 16.06% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
